Cancelled: Psychopharmacologic Drugs Advisory Committee

The Committee to discuss new drug application (NDA) 209241, Valbenazine 40 mg capsules, for the proposed treatment of Tardive Dyskinesia, submitted by Neurocrine Biosciences, Inc. has been cancelled.